Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the first participant has been dosed in IMPACT DUCHENNE, the Company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne).
IMPACT DUCHENNE and the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trials are components of an integrated, multi-trial clinical development program designed to evaluate the safety and efficacy of a single intravenous dose of SGT-003 in individuals living with Duchenne.
Read more about Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy.
